Lloyd Rigler Sleep Apnea Research Laboratory, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
J Sleep Res. 2009 Dec;18(4):397-403. doi: 10.1111/j.1365-2869.2009.00754.x. Epub 2009 Aug 3.
Sleep-disordered breathing is much more prevalent in elderly people than in middle-aged or young populations, but its clinical significance in this age group is unclear. This study investigated retrospectively the rates of all-cause mortality in elderly people (>or= 65 years) with a laboratory diagnosis of sleep apnoea, and compared their rates of mortality with that of age-, gender- and ethnicity-matched national mortality data. Survival of 611 elderly people was ascertained after a follow-up of 5.17 +/- 1.13 years. Their age was 70.4 +/- 4.8 years, body mass index 30.4 +/- 5.9 kg m(-2) and respiratory disturbance index (RDI) 28.9 +/- 20.1 events h(-1). Seventy-five (12.27%) patients died during the follow-up period. In comparison with the demographically matched cohort from the general population, the standardized mortality rate of the sleep laboratory cohort was 0.67 [95% confidence interval (CI): 0.53-0.88; chi(2) = 11.69, P < 0.0006]. When calculated separately for patients with RDI < 20 (no/mild apnoea), RDI 20-40 (moderate apnoea) and RDI > 40 events h(-1) (severe apnoea) there was a significant survival advantage for the moderate group with a standardized mortality rate of 0.42 (P < 0.0002), while elderly people with no/mild apnoea tended to have lower mortality and those with severe sleep apnoea had the same mortality as the matched population cohorts. Cox regression analysis revealed that sleep latency and comorbidities but not sleep apnoea severity were associated independently with mortality. The survival advantage of elderly people with moderate sleep apnoea, combined with recent findings on the potential cardioprotective effects of chronic intermittent hypoxia, raise the possibility that apnoeas during sleep may activate adaptive pathways in the elderly.
睡眠呼吸障碍在老年人中比在中年或年轻人中更为普遍,但在这个年龄段其临床意义尚不清楚。本研究回顾性调查了实验室诊断为睡眠呼吸暂停的老年患者(≥65 岁)的全因死亡率,并将其死亡率与年龄、性别和种族匹配的国家死亡率数据进行了比较。在随访 5.17±1.13 年后,确定了 611 名老年人的生存情况。他们的年龄为 70.4±4.8 岁,体重指数为 30.4±5.9kg/m2,呼吸紊乱指数(RDI)为 28.9±20.1 次/h。在随访期间,75 名(12.27%)患者死亡。与一般人群中人口统计学匹配的队列相比,睡眠实验室队列的标准化死亡率为 0.67[95%置信区间(CI):0.53-0.88;卡方=11.69,P<0.0006]。当分别计算 RDI<20(无/轻度呼吸暂停)、RDI20-40(中度呼吸暂停)和 RDI>40 次/h(重度呼吸暂停)的患者时,中度组的生存率有显著优势,标准化死亡率为 0.42(P<0.0002),而无/轻度呼吸暂停的老年患者死亡率较低,重度睡眠呼吸暂停患者的死亡率与匹配人群队列相同。Cox 回归分析显示,睡眠潜伏期和合并症而非睡眠呼吸暂停严重程度与死亡率独立相关。中度睡眠呼吸暂停的老年患者的生存优势,加上最近关于慢性间歇性低氧对心脏的潜在保护作用的发现,提示睡眠中的呼吸暂停可能会激活老年患者的适应性途径。